Ligand Pharmaceuticals | LGND - Net Income


Ligand Pharmaceuticals reported $-13.34M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Agenus USD -10.63M 74.49M Dec/2025
Amgen USD 1.82B 486M Mar/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
Baxter International USD -15M 1.11B Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Enviri Corporation USD -84.28M 61.97M Dec/2025
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
MacroGenics USD -14.16M 30.98M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Pacira USD 2.92M 1.28M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Veracyte USD 28.71M 12.44M Mar/2026